In part two of Pharmaceutical Commerce’s conversation with Austin Russian, SVP of Program Excellence at PANTHERx Rare, ...
Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction that expands its presence in the US rare ...
In the second part of her interview with Pharmaceutical Commerce live from Asembia AXS26, Jennifer Lospinoso, managing ...
Miranda Delatore and Megan Wetzel share their outlook on the future of specialty pharmacy.
Will Shrank, MD, explains how the specialty pharma pipeline could pose access risks in the future. In the second part of his interview with Pharmaceutical Commerce, live from Asembia AXS26 in Las ...
First up, Eli Lilly has opened its first dedicated genetic medicine facility in Lebanon, Indiana. The company says the site ...
Jessica Lovett discusses specialty pharma commercialization timelines, and how the Canadian market is different from the US.
Tommy Bramley explains how real-world evidence can be leveraged to benefit patient outcomes in specialty pharma.
PBM reform is accelerating via FTC settlements and CAA 2026, mandating data reporting, rebate pass-through in Part D, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results